2-chloro-5-(2-furyl)pyrimidine | 63558-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-5-(2-furyl)pyrimidine
• 英文别名: 2-Chlor-5-(2-furyl)pyrimidin；2-chloro-5-furan-2-yl-pyrimidine；2-chloro-5-(furan-2-yl)pyrimidine
• CAS: 63558-66-7
• 化学式: C₈H₅ClN₂O
• 分子量: 180.593
• InChiKey: PFZVWPHANKXXRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  哌啶 、 2-chloro-5-(2-furyl)pyrimidine 以 1,4-二氧六环 、 水 为溶剂， 生成 5-(2-furyl)-2-N-piperidinylpyrimidine
  参考文献：
  名称：

  Allen, David W.; Buckland, David J.; Hutley, Barrie G., Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie, 1980, vol. 35, # 4, p. 463 - 467

  摘要：

  DOI：
• 作为产物：
  描述：

  呋喃 、 2-氯-5-碘嘧啶 以 乙腈 为溶剂， 生成 2-chloro-5-(2-furyl)pyrimidine
  参考文献：
  名称：

  Allen,D.W. et al., Journal of the Chemical Society. Perkin transactions I, 1977, p. 621 - 624

  摘要：

  DOI：

文献信息

• HETEROCYCLIC AMINE DERIVATIVES
  申请人：Galley Guido

  公开号：US20120245172A1

  公开（公告）日：2012-09-27

  The present invention relates to compounds of formula I wherein A, B, X, Y, Ar, R 1 , R 2 , R′, m and n are as defined herein and to pharmaceutical active acid addition salts thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中A、B、X、Y、Ar、R1、R2、R′、m和n的定义如本文所述，并且涉及其药用活性酸盐。式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、以及代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍、以及心血管疾病。
• [EN] HETEROCYCLIC AMINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINES HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012126922A1

  公开（公告）日：2012-09-27

  The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, -O-CH2-C3-6-cycloalkyl, -O-(CH2)2-O-lower alkyl, S(O)2CH3, SF5, -C(O)NH-lower alkyl, phenyl, -O-pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen, or is benzyl, oxetanyl or furanyl; m Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo[d][1.3]dioxolyl, 5,6,7,8- tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl, or 1,3,4-oxadiazolyl; Y is a bond, -CH2-, -CH2CH2-, -CH(CF3)- or -CH(CH3)-; R2 is hydrogen or lower alkyl; A is CR or N; and R is hydrogen, cyano, halogen or lower alkyl; R' is hydrogen or halogen; with the proviso that when R' is halogen, then A is CH; B is CH or N; n is 0, 1 or 2; X is a bond, -CH2- or -O-; pharmaceutical active acid addition salts thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及以下式（I）的化合物，其中R1是氢、低碳基、卤素、被卤素取代的低碳基、低烷氧基、被卤素取代的低烷氧基、氰基、硝基、C3-6环烷基、-CH2-C3-6环烷基、-O- -C3-6环烷基、-O-( )2-O-低碳基、S(O)2 、SF5、-C(O)NH-低碳基、苯基、-O-嘧啶基，或是被低烷氧基取代的被卤素取代的苯基、或者是苄基、氧杂环戊二烯基或呋喃基；m Ar是芳基或杂芳基，选自苯基、萘基、嘧啶基、吡啶基、苯并噻唑基、喹啉基、喹唑啉基、苯并[d][1.3]二噁基、5,6,7,8-四氢喹唑啉基、吡唑基、吡嗪基、吡啶啉基或1,3,4-噁二唑基；Y是键、- -、- -、-CH(CF3)-或-CH(CH3)-；R2是氢或低碳基；A是CR或N；R是氢、氰基、卤素或低碳基；R'是氢或卤素；但是如果R'是卤素，则A是CH；B是CH或N；n是0、1或2；X是键、- -或-O-；以及它们的药用活性酸盐。现已发现，式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• Benzenesulfonamide derivative and process for preparing thereof
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US05728706A1

  公开（公告）日：1998-03-17

  A benzenesulfonamide derivative of the formula \x9bI!: ##STR1## wherein Ring A and Ring B are the same or different and each substituted or unsubstituted benzene ring, Q is a single bond or a group of the formula: --O--, --S--, --SO--, --SO.sub.2 -- or --CH.sub.2 --, Y is a group of the formula: --O--, --S-- or --NH--, Alk is lower alkylene group or lower alkenylene group, Z is a single bond or a group of the formula: --O-- or --NH--, R is a substituted or unsubstituted aromatic heterocyclic or aryl group, R.sup.1 is hydrogen atom, trifluoromethyl group, substituted or unsubstituted lower alkyl group, substituted or unsubstituted lower alkenyl group, mono- or di-lower alkylamino group, substituted or unsubstituted lower alkylthio group, substituted or unsubstituted lower alkoxy group, substituted or unsubstituted lower alkynyl group, aromatic heterocyclic group, substituted or unsubstituted aliphatic heterocyclic group or aryl group, provided that when Z is a single bond, R is a substituted or unsubstituted aromatic heterocyclic group, or a pharmaceutically acceptable salt thereof, and processes for preparing the same, these compounds having endothelin antagonistic activity and being useful in the prophylaxis or treatment of various diseases caused by endothelin.

  该化合物为苯磺酰胺衍生物，其化学式为：\x9bI!: ##STR1## 其中环A和环B可以相同或不同，每个环都是取代或未取代的苯环，Q是单键或公式为：--O--，--S--，--SO--，--SO.sub.2--或--CH.sub.2--的基团，Y是公式为：--O--，--S--或--NH--的基团，Alk是较低的烷基或较低的烯基烷基，Z是单键或公式为：--O--或--NH--的基团，R是取代或未取代的芳香杂环或芳基基团，R.sup.1是氢原子、三氟甲基基团、取代或未取代的较低烷基基团、取代或未取代的较低烯基基团、单-或双-较低烷基氨基基团、取代或未取代的较低烷基硫基基团、取代或未取代的较低烷氧基团、取代或未取代的较低炔基基团、芳香杂环基团、取代或未取代的脂肪族杂环基团或芳基基团，但当Z为单键时，R为取代或未取代的芳香杂环基团，或其药学上可接受的盐。该化合物具有内皮素拮抗活性，可用于预防或治疗由内皮素引起的各种疾病，并提供制备该化合物的方法。
• ALLEN D. W.; BUCKLAND D. J.; HUTLEY B. G.; OADES A. C.; TURNER J. B., J. CHEM. SOC. PERKIN TRANS., 1977, PART 1,
  作者：ALLEN D. W.、 BUCKLAND D. J.、 HUTLEY B. G.、 OADES A. C.、 TURNER J. B.

  DOI：——

  日期：——
• US5589478A
  申请人：——

  公开号：US5589478A

  公开（公告）日：1996-12-31